Project Grant R01CA299257
Award Date
4/3/25
Completion Date
3/31/30
Dollars Obligated
$643K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This $984,000 federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), aims to advance the treatment of immune-resistant cancers. The grant will fund research at the University of Texas Southwestern Medical Center to integrate nanotechnology, STING signaling, dendritic cell biology, and immuno-oncology approaches. Key objectives include designing a pH-sensitive, hypoxia-activated nanoparticle STING agonist to selectively...
This federal Project Grant award, totaling $701,876 and funded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), will support a research project titled "A Systems-Level Approach to Therapeutically Target STING in Cancer" at Weill Medical College of Cornell University. The project aims to utilize a novel technology called SatSeq to map the structure-function landscape of the immune-related protein STING and its role in cancer progression. Specifically, the...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $935,004 over a 5-year period from July 1, 2024 to June 30, 2029 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The objective is to elucidate the mechanisms by which tumor-infiltrating T cells experience cell death induced by the STING signaling pathway in response to cyclic GMP-AMP (cGAMP) importation, and to develop strategies for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $499,238 in funding to Yale University to develop and test a novel tumor-targeted STING agonist (PHLIP-STINGA) that can enhance the effects of DNA-damaging therapies, such as radiation and chemotherapy, for the treatment of head and neck squamous cell carcinoma (HNSCC).
The key objectives are to: 1) Optimize the PHLIP-STINGA compound to overcome limitations of existing STING...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is providing $1,876,547.00 to New York University School of Medicine to conduct research aimed at optimizing T cell receptor (TCR)-CD3 signaling for cancer immunotherapy. The project will use in vitro methods, structural analysis, and in vivo testing to identify TCR mutations that can enhance immune-mediated tumor killing without losing antigen specificity. The goal is to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $544,478 to The University of Texas Southwestern Medical Center to conduct research on the metabolic pathways involved in purine nucleotide synthesis in cancer. The researchers will use stable isotope infusions and metabolomics to determine the relative contributions of the de novo synthesis and salvage pathways to maintaining purine nucleotide pools in tumors. They will investigate...
The National Cancer Institute awarded a $407,113 Project Grant (CFDA 93.396 - Cancer Biology Research) to Trustees of Boston University for the development of bio-orthogonal mid-infrared photothermal imaging technology to study cancer metabolism. This 3-year award, running from September 1, 2024 to August 31, 2027, aims to: 1) build a library of nitrile-based probes to sense molecular events in cancer cells; 2) develop nitrile-tagged small molecules to measure nutrient metabolism; and 3)...
The National Cancer Institute (NCI) awarded a $415,257 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Methodist Hospital Research Institute in Houston, Texas. The grant, effective July 1, 2024 through June 30, 2026, will fund research to explore how targeting the stress granule regulatory network and metabolic stress response pathways can improve the efficacy and longevity of chimeric antigen receptor (CAR) T-cell therapies for cancer treatment. The research aims to analyze...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,658 to New York University School of Medicine to conduct research on understanding the regulation of pyrimidine metabolism and its impact on cancer cell function and anti-tumor immunity. The research aims to:
Determine how pyrimidine overflow and disruption of the p53-dependent ribosome biogenesis checkpoint differentially affect cancer cells versus anti-cancer immune...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $656,237 to Duke University to develop nucleic acid binding polymers that can scavenge extracellular nucleic acid-containing damage-associated molecular patterns (DAMPs) in the setting of pancreatic cancer therapy. The goal is to safely and effectively mitigate the activation of cancer cell migration and metastasis that can occur due to the release of such DAMPs during...